Literature DB >> 12081009

Immune responses to myxoma virus.

Peter Kerr1, Grant McFadden.   

Abstract

Myxoma virus causes the systemic disease myxomatosis in the European rabbit (Oryctolagus cuniculus). Originating in the South American rabbit Sylvilagus brasiliensis, where it causes a relatively localized fibroma, myxoma virus is a classic example of a virus that has jumped species to produce an exotic disease and then coevolved with its new host. Like other poxviruses, myxoma virus encodes multiple proteins capable of downregulating the host innate and acquired immune responses. Other virus-encoded proteins enable replication in host lymphocytes and monocytes, for example, by inhibiting apoptosis. Detailed studies on these proteins have demonstrated novel methods of interactions with the host immune system and added substantially to the understanding of the interaction of large DNA viruses with their hosts. Despite the increasingly detailed molecular knowledge of myxoma virus, relatively little is known about the dynamics of the interaction of the virus with the integrated host-immune system during infection and, in particular, about the evolution of resistance to the virus in wild rabbits or the species barrier. This review will focus on the detailed molecular studies that have been done with myxoma virus and discuss the more limited knowledge of the pathogenesis of myxoma virus in rabbits and the ways that the consolidated immune responses may determine genetic resistance to myxomatosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12081009     DOI: 10.1089/08828240260066198

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  37 in total

Review 1.  Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.

Authors:  Guido Wollmann; Koray Ozduman; Anthony N van den Pol
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  Myxoma virus: propagation, purification, quantification, and storage.

Authors:  Sherin E Smallwood; Masmudur M Rahman; Dorothy W Smith; Grant McFadden
Journal:  Curr Protoc Microbiol       Date:  2010-05

3.  Myxoma virus lacking the pyrin-like protein M013 is sensed in human myeloid cells by both NLRP3 and multiple Toll-like receptors, which independently activate the inflammasome and NF-κB innate response pathways.

Authors:  Masmudur M Rahman; Grant McFadden
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

4.  Oncolytic Poxviruses.

Authors:  Winnie M Chan; Grant McFadden
Journal:  Annu Rev Virol       Date:  2014-09-01       Impact factor: 10.431

5.  Structure of M11L: A myxoma virus structural homolog of the apoptosis inhibitor, Bcl-2.

Authors:  Andrew E Douglas; Kevin D Corbett; James M Berger; Grant McFadden; Tracy M Handel
Journal:  Protein Sci       Date:  2007-04       Impact factor: 6.725

6.  Myxoma and vaccinia viruses bind differentially to human leukocytes.

Authors:  Winnie M Chan; Eric C Bartee; Jan S Moreb; Ken Dower; John H Connor; Grant McFadden
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

7.  Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.

Authors:  Xue Qing Lun; Hongyuan Zhou; Tommy Alain; Beichen Sun; Limei Wang; John W Barrett; Marianne M Stanford; Grant McFadden; John Bell; Donna L Senger; Peter A Forsyth
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

8.  Induction of alpha/beta interferon by myxoma virus is selectively abrogated when primary mouse embryo fibroblasts become immortalized.

Authors:  Fuan Wang; John W Barrett; Yiyue Ma; Gregory A Dekaban; Grant McFadden
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

9.  Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma.

Authors:  Darnell T Josiah; Dongqin Zhu; Fernanda Dreher; John Olson; Grant McFadden; Hannah Caldas
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

10.  Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.

Authors:  Yushui Wu; Xueqing Lun; Hongyuan Zhou; Limei Wang; Beichen Sun; John C Bell; John W Barrett; Grant McFadden; Jaclyn A Biegel; Donna L Senger; Peter A Forsyth
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.